Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesOlecranon bursitis in patients treated with sunitinib for renal cell carcinoma
Medical Oncology, 05/19/09
Gregory T et al. - In a report of 2 cases of pts with metastatic renal cell cancer (RCC) who developed olecranon bursitis while receiving sunitinib, the pathophysiology of this event remains unexplained, although some hypotheses are described.
Methods- Sunitinib is a recently approved tyrosine-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR).
- In both cases, other causes of bursitis were excluded and symptoms resolved after treatment with sunitinib was discontinued.
- Recurrence of symptoms during subsequent treatment cycles was observed.
- This adverse event has not been previously reported for sunitinib and it is believed to be directly attributable to the drug.
- This is an unexpected adverse event, given the mechanism of action of the drug.
Related Articles
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Journal of Clinical Oncology, 11/24/09
Relevance Score: 89%
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 89%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 88%
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 87%
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Relevance Score: 87%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/20/09
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/20/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of urinary bladder cancer: a case-control analysis of industry and occupation
BMC Cancer, 12/20/09
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas
Annals of Diagnostic Pathology, 12/20/09
High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors
Cancer Research, 12/19/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Journal of the National Cancer Institute, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor